Reducing the time to develop and manufacture formulations for first-in-human (FIH) testing is a key part of the product development timeline. This paper discusses approaches to shorten this time, reviewing advantages and disadvantages of various formulation types. A process flowchart is presented to help formulation scientists select an appropriate formulation that can minimize the required resources and rapidly deliver a functional formulation for clinical testing. The required data for each type of formulation and alternatives [e.g., microdosing and chemical-in-capsule-in-bottle (CICICB) approaches] are also discussed.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.